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Abstract
Objective. This study aimed to compare the sensitivity, speciﬁcity, positive predictive value (PPV) and negative predictive value
(NPV) of urine cytology, BladderChek nuclear matrix protein-22 (NMP22) and UroVysion ﬂuorescence in situ
hybridization (FISH) tests in patients with newly diagnosed bladder cancer, those with recurrent bladder cancer, and those
with bladder cancer but in remission during surveillance. Material and methods. Voided urine samples obtained from
178 patients with suspected or known bladder cancer about to undergo diagnostic or surveillance cystoscopy and 25 control
subjects without the disease were divided into four and used for urine culture and cytology, NMP22 BladderChek and
UroVysion FISH tests. The sensitivity, speciﬁcity, PPV and NPV for each test were calculated. Comparison was made between
the ability of each test to detect bladder cancer in the three category of patients listed. Results. Of the 178 patients with bladder
cancer, 43 were newly diagnosed, 58 had recurrent disease and 77 were in remission. The sensitivity of each test in newly
diagnosed patients was: urine cytology 28%, NMP22 88% and FISH 80%; and in patients with recurrent disease: urine
cytology 33%, NMP22 57% and FISH 85%. The mean speciﬁcity for urine cytology, NMP22 and FISH was 95%, 67% and
48%, respectively. Conclusion.Of the tests used in the study for detection of bladder cancer, NMP22 appeared to be most cost-
effective and rapid, with relatively high sensitivity and speciﬁcity in all categories of patients. The NMP22 test may be
considered a new gold standard for the assessment of patients with known or suspected bladder cancer.
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Introduction
For patients diagnosed with bladder cancer close
surveillance using urine cytology and cystoscopy is
indicated to identify tumour recurrence and prevent
disease progression. Cystoscopy and urine cytology
are the current standard monitoring tools for super-
ﬁcial bladder cancer. Cytology exhibits variable sen-
sitivity depending on tumour grade, with the lowest
sensitivity for low-grade tumours [1]. Interpretation
of urine specimens also depends on the skill of the
examiner [2]. The sensitivity of cystoscopy is limited
to the tumour that can be visualized, and ﬂat in situ
carcinomas are often missed. Frequent follow-up
cystoscopies are expensive and cause some discomfort
for the patients. Consequently, a non-invasive, objec-
tive and easy-to-perform diagnostic test that detects
bladder tumours and has a high speciﬁcity could
improve the follow-up of patients with superﬁcial
bladder cancer [3–8]. Furthermore, the assessment
of patients with haematuria-sensitive urine-based
marker assays, particularly those that provide point-
of-care results, may not only improve the diagnosis of
bladder cancer, but also shorten the time to make a
diagnosis [3–5]. Numerous candidate urinary bio-
markers for detecting bladder cancer have been devel-
oped in the past 10 years. The most intensively
studied markers include the BTA Stat Test,
nuclear matrix protein-22 (NMP22), UroVysion
ﬂuorescence in situ hybridization (FISH) and
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survivin. As there is no consensus among urologists
about the best tests to incorporate into routine clinical
practice, there is a need to continue to assess the
utility of these markers in different parts of the world.
The ideal urinary tumour biomarker should have
the following features: high sensitivity, i.e. low false
negatives, and high speciﬁcity, i.e. low false positives.
A tumour marker with low sensitivity will result in
underdiagnosis, impaired cancer control and false
hope. A tumour marker with low speciﬁcity will
produce unnecessary anxiety and unwarranted inves-
tigations. Urine cytology, introduced into clinical
practice by Papanicolaou and Marshall in 1945, has
a sensitivity of about 30% and a speciﬁcity of about
85% in most centres, and is operator dependent [9].
The UroVysion FISH assay (Vysis, IL, USA) is a
multitarget assay that detects aneuploidy of chromo-
somes 3, 4 and 17 and loss of the 9p21 band in
exfoliated cells in urine from patients with transitional
cell carcinoma (TCC) [3,8]. The NMP22 test detects
elevated amounts of nuclear mitotic apparatus pro-
tein, a component of the nuclear matrix essential for
cell division that is released into urine at cell death
[5,6,8]. UroVysion FISH and NMP22 BladderChek
test (Matritech, Newton, MA, USA) have been
reported to have higher sensitivity and speciﬁcity
than urine cytology in patients with cystoscopic and
histological TCC either at initial diagnosis or on
recurrence. They are both approved by the US
Food and Drug Administration (FDA) for use as
urinary tumour makers.
The aim of this study was to compare the sensitivity
and speciﬁcity of urine cytology, urinary NMP22
qualitative test (positive or negative) and UroVysion
FISH assay in patients with newly diagnosed bladder
cancer, recurrent bladder cancer and known TCC of
the bladder but without tumour recurrence during
surveillance (i.e. in remission) in a Urology Unit in
Kuwait, a Middle Eastern country with a bladder
cancer spectrum slightly different from that reported
in many Western countries.
Material and methods
Voided urine samples collected before cystoscopy in
178 patients with or without previously diagnosed
TCC of the bladder was subjected to urine culture,
urine cytology, urinary NMP22 qualitative test and
UroVysion FISH assay in a blinded fashion. There
were 25 controls. These were patients with no
macroscopic or microscopic haematuria undergoing
diagnostic cystoscopy. Most of the controls had non-
speciﬁc irritative symptoms. Smokers were excluded
from the control arm. This was done to avoid
introducing confounding factors in the control arm
as some of the smokers may have yet undiagnosed
upper tract urothelial tumours. About 80% of patients
with TCC in this centre are smokers. All cystoscopies,
bladder biopsies, transurethral resection of bladder
tumour (TURBT) and examination of patients under
anaesthesia to determine tumour stage were carried
out by one experienced consultant urological surgeon
(EOK). Only white light cystoscopy was used in this
study. Patients had a complete work-up including
intravenous urography (IVU), bone scan and com-
puted tomographic (CT) scan of the abdomen and
pelvis to stage accurately those with bladder cancer.
All laboratory analyses indicated below were carried
out in a blinded fashion. No bladder wash urinary
specimens were used in this study.
All the patients who underwent cystoscopy had a
bladder biopsy. Biopsies were taken as follows. In
patients found to have bladder tumours at cystocopy,
bladder tumour section and normal-looking sections
of the bladder were taken; in patients without any
tumours found, a four-quadrant random bladder
biopsy was taken in addition to the area of the trigone
(i.e. a minimum of four biopsies per patient). Thus,
bladder tissue was available from all 203 patients
studied. The initial diagnosis of bladder TCC was
based on history, radiological ﬁndings on IVU or CT
scan of a ﬁlling defect in the bladder, cystoscopy,
TURBT specimens or bladder biopsies. Patients with
a known ongoing urinary tract infection (UTI) at the
time of cystoscopy, urolithiasis, TCC of the renal
pelvis or ureter, and patients with squamous cell or
adenocarcinoma of the bladder were excluded from
the study. The study received local ethics committee
approval and the patients signed relevant informed
consent forms.
Preparation of urine samples for cytopathological
examination
Four cytospins were prepared from the urine sample
using a ThermoShandon cytocentrifuge. If the cell
pellet had a bloody appearance, 30 ml of CytoLyt
solution was added. The cytospins were ﬁxed in 95%
ethanol overnight and stored at –20C until staining
was carried out. Papanicolaou staining was done on
one of the cytospins. Slides were read as follows:
malignant cells present, benign cells only, suspicious
cells or atypia. Other signiﬁcant ﬁndings such as the
presence of inﬂammatory cells, fungal organisms (e.g.
Candida sp.) or parasites (e.g. Schistosomiasis haema-
tobium) were indicated in the ﬁnal report. All cyto-
pathological analyses were performed by one
experienced cytopathologist (KK).
2 E. O. Kehinde et al.
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Tissue histology
Following cystoscopy, biopsy samples or TURBT
specimens obtained were ﬁxed in 4% formaldehyde
solution and sent for histological examination using
routine processing into parafﬁn and standard hae-
matoxylin and eosin (H&E) staining techniques.
Pathological grade and stage were determined.
Tumours were graded according to the World
Health Organization (WHO) classiﬁcation, where
G1 and G2 were classiﬁed as low-grade and G3 as
high-grade tumour. All pathological examinations
were carried out by one experienced pathologist
(JTA). Categorization of patients into newly diag-
nosed cases, those with recurrent disease or those in
remission was based on both clinical history and
tissue histology.
Nuclear matrix protein-22 qualitative assay
The newer point-of-care version of the NMP22
qualitative assay kits (the BladderChek test;
Matritech, Newton, MA, USA) was used. Follow-
ing the kit manufacturer’s instructions, four drops of
unprocessed urine was added to the sample well
and allowed to react for 30 min. A positive
test was indicated by the appearance of a line
in the C and T sections of the well, as shown
in Figure 1 (A, B). Some cases, which after cystos-
copy and bladder biopsy turned out to have low-
grade TCC, gave an equivocal NMP22 reading
(Figure 1C). In these cases the “T” line of the
NMP22 well appeared very faint. For the purpose
of this study, such cases were regarded as negative.
All NMP22 assay results were read by a trained
technician.
UroVysion ﬂuorescence in situ hybridization analysis
Following the standard protocol as per the kit
manufacturer’s instructions (Abbott, IL, USA), the
FISH technique was successfully developed for
detecting chromosomal patterns of normal transi-
tional epithelium and those of TCC of the bladder,
as shown in Figure 2. After FISH preparation, the
images were captured using a ﬂuorescent AxioPlan
microscope operated with Metapher software (Meta-
systems, Germany). Scoring was performed as recom-
mended by UroVysion Proﬁciency Panel instructions
with at least 21–25 cells counted per patient.
A positive FISH result was deﬁned as: (i) ﬁve tran-
sitional cells or greater with a gain of two or more
chromosomes 3, 7 or 17, and/or (ii) 12 cells or more
with 9p21 deletion. All UroVysion FISH analyses
were carried out by one experienced molecular
pathologist (FA) who was blinded to the diagnosis.
Non- analysable urine samples
Some urine specimens were not analysable for the
following reasons. For urine cytology, there was little
or no cellular material after cytospin to enable the
cytopathologist to make a deﬁnite diagnosis about
the absence or presence of malignant cells. This
was true for patients with small bladder cancer or
those with very tiny recurrences. For the NMP22 test,
some results were equivocal, i.e. neither positive nor
negative. For the UroVysion FISH test, for unknown
reasons distorted chromosomes or no chromosomes
were isolated from some urine samples.
These categories of urine sample were excluded
from further analysis, based on the premise that a test
would be considered positive or negative if enough
A B C
Figure 1. Nuclear matrix protein-22 (NMP22) BladderChek test. (A) Negative (–); (B) positive (+); (C) equivocal (±).
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cellular or chromosomal material were available to
make a correct diagnosis.
Deﬁnitions:
In this study, the following deﬁnitions have been used:
. sensitivity = TP/(TP + FN) (i.e. tumour positive)
. speciﬁcity = TN/(TN + FP) (i.e. tumour negative)
. PPV = TP/(TP + FP)
. NPV = TN/(TN + FN)
. diagnostic accuracy = (TP + TN)/n, where
n = TP + FN + FP + TN
where TP = true positive, FN = false negative,
TN = true negative, FP = false positive,
PPV = positive predictive value, and NPV = negative
predictive value.
The sensitivity, speciﬁcity, PPV and NPV of urine
cytology, NMP22 and UroVysion FISH assay were
compared in patients with newly diagnosed bladder
TCC, patients with recurrent bladder TCC and those
in remission. Factors affecting the sensitivity of the
test (i.e. giving false-positive test results) were ana-
lysed. Furthermore, the effect of the ﬁnal histological
grade and stage of tumour on the sensitivity of each
urine marker test was analysed.
Statistical analysis
All data management and analyses were conducted
using SPSS software (SPSS, Chicago, IL, USA). The
chi-squared (c2) or Fischer’s exact test was used to
examine the association between categorical variables,
and the normal Z test was used to assess the signiﬁcant
difference between two proportions. The t test was
used to compare the means of two independent
groups. A p value of < 0.05 was considered statistically
signiﬁcant.
Results
As shown in Table I, there were 43, 58 and 77 patients
with newly diagnosed TCC, recurrent TCC and
known TCC but in remission, respectively.
Twenty-ﬁve patients who underwent cystoscopy but
had no bladder outlet obstruction were used as con-
trols. Bladder biopsies in the control group showed
neither inﬂammation nor the presence of urothelial
tumour.
Table I shows the mean (range) age, pathological
stage and grade of the patients studied. Patients with
newly diagnosed bladder TCC had higher stage dis-
ease than those who had recurrent disease. Most of
the patients presented with low-grade disease
(Table I). The patients presented at an earlier age
than those reported in the literature. More than 80%
were smokers.
Table II shows the positivity of each test versus the
type of patients. The positivity of urine cytology
increased from 28% in patients with newly diagnosed
TCC to 33% in those with recurrent tumour
(p < 0.11) with a speciﬁcity of 95%. The positivity
of NMP22 decreased from 82% for patients with
newly diagnosed TCC to 57% in those with recurrent
TCC bladder. NMP22 had an overall speciﬁcity of
67%. The ability of FISH to diagnose bladder TCC
improved from 81% in patients with newly diagnosed
bladder cancer to 85% in those with recurrent
tumour. The overall speciﬁcity of FISH was 48%.
In this series of patients, urine cytology had the high-
est speciﬁcity, followed by NMP22 and by UroVysion
FISH (Tables I–IV).
Table II also shows the relationship between tumour
tissue grade and positivity of each test. The positivity of
urine cytology increased with tumour grade, being 70%
for grade 3 and 12% for grade 1 tumour (p < 0.0001).
NMP22 and FISH had 100% positivity regardless of
the grade of the tumour. Data in Table II further
indicate that when tumour was present, irrespective
A B
Figure 2. UroVysion test showing ﬂuorescence in situ hybridization (FISH) signals on the interphase nuclei of the bladder epithelial cells in a
control subject and a patient with transitional cell carcinoma (TCC) of the bladder. (A) Control: UroVysion FISH test showing two copies of
chromosomes 3 (red), 7 (green), 9 (gold) and 17 (aqua) in normal bladder transitional epithelium; (B) positive for TCC of bladder: UroVysion
FISH test showing chromosomal aneusomy in chromosomes 3, 7, 9 and 17 with translocation between chromosomes 3 and 9.
4 E. O. Kehinde et al.
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of tumour grade, the NMP22 and FISH test had the
highest detection rates, while for urine cytology, the
higher the tumour grade the higher its sensitivity.
The overall performance characteristics of each test
to detect the presence of urothelial tumours are shown
in Tables III and IV.
Factors that gave rise to false positive results with
the tumour markers were further analysed retrospec-
tively and found to include mild to moderate UTI,
presence of urolithiasis, presence of benign prostatic
hyperplasia in men and recent treatment with intra-
vesical chemotherapy, particularly bacille Calmette–
Guérin (BCG), within 8 weeks of the test.
The mean time taken to obtain results per test in
this centre was as follows: urine cytology 44 (range
36–72) h, NMP22 BladderChek test 0.67 (range 0.5–
0.83) h and UroVysion FISH 56 (48–72) h. The mean
cost per test was about US $14.00, $24.00 and
$250.00 for the NMP22 test, urine cytology and
UroVysion FISH, respectively.
Table I. Pathological grade, stage and proﬁle of patients with bladder cancer.
Total no. of casesa Newly diagnosed Recurrent pb In remission Control Gross totalc
Grade
1 55 23 (53.5) 32 (55.2) 0.09 45 (58.4) 100 (56.2)
2 36 13 (30.2) 23 (39.7) 0.06 27 (35.1) 63 (35.4)
3 10 7 (16.3) 3 (5.1) 0.001 5 (6.5)d 15 (8.4)
Total (n) 101 43 (100) 58 (100) 77 (100) 25 203 (100)
Stage
CIS 6 4 (9.3) 2 (3.4) 0.001 9 (11.7) 15 (8.4)
Superﬁcial
pTa 6 4 (9.3) 2 (3.4) 0.001 22 (28.6) 28 (15.7)
pT1 54 17 (39.5) 37 (63.9) 0.1 42 (54.5) 96 (53.9)
Invasive
pT2 16 7 (16.3) 9 (15.5) 0.1 4 (5.1) 20 (11.2)
pT3 9 5 (11.5) 4 (6.9) 0.07 0 (0) 9 (5.1)
pT4 10 6 (14.0) 4 (6.9) 0.001 0 (0) 10 (5.6)
Total 101 43 (100) 58 (100) 77 (100) 25 203 (100)
Age (years), mean (range) 53 (16–77) 57 (23–71) 59 (16–76) 55 (20–70) 57 (16–76)
Data are shown as n (%).
aThe numbers shown in this column represent the total number of patients recruited and with tissue available for histological analysis following
bladder biopsy or transurethral resection of bladder tumour. bFischer’s exact test. cGross total includes patients with disease and those in
remission and control subjects. dPatients with grade 3 or stage > pT1 urothelial tumour considered for cystectomy except it is very focal in
nature or patient was subjected to partial cystectomy.
Table II. Comparison of positive urine cytology (UC), nuclear matrix protein-22 (NMP22) and ﬂuorescence in situ hybridization (FISH) tests
with clinical type and grade of bladder cancer.
Tests
Clinical type of cancer UC +ve NMP22 +ve FISH +ve Gross na
Newly diagnosed n = 10/36 (28%) n = 31/38 (82%) n = 33/41 (81%) 43
Recurrent TCC n = 9/27 (33%) n = 20/35 (57%) n = 17/20 (85%) 58
In remission (FP) n = 3/56 (5.4%) n = 26/77 (33%) n = 13/25 (52%) 77
Tumour grade
1 n = 3/25 (12.0%) n = 25/25 (100%) n = 25/25 (100%) 55a
2 n = 8/15 (53.3%) n = 15/15 (100%) n = 15/15 (100%) 36a
3 n = 7/10 (70%) n = 10/10 (100%) n = 10/10 (100%) 10a
Analysis excluded patients found to have too few cells to allow analysis by UC, those with equivocal NMP22 tests and those where no
chromosomes were isolated on UroVysion FISH. Most of these were patients with very small tumours or small recurrences. A major cause of
false-positive NMP22 and FISH tests was low-grade urinary tract infection (102–104 cfu/ml) with no organisms cultured. Under tumour grade,
comparison was made between the tests in those with deﬁnitive positive or negative urine cytology ab initio.
aGross number (n) of patients recruited per patient category.
TCC = transitional cell cancer; FP = false positive.
Urinary tumour markers and bladder cancer 5
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Discussion
The ideal bladder cancer tumour marker should be
objective, non-invasive, reproducible, and easy and
inexpensive to administer and interpret, and must
also possess high sensitivity and speciﬁcity [6,7]. In
addition, it should be possible to assay the marker in
voided urine samples. The availability of point-of-care
tests resulting in immediate results is highly desirable,
since tests that require special processing and analysis,
such as enzyme-linked immunosorbent assay
(ELISA), reverse-transcription–polymerase chain
reaction (RT-PCR) or FISH will lead to delays in
the results [7]. A test that permits quantitative assay is
also desirable as the changes in the concentration of
the marker in the urine may be helpful in clinical
decision making, as is the case of prostate-
speciﬁc antigen (PSA) in patients with prostate can-
cer. A recent comprehensive literature review by van
Rhijn et al. [10] calculated sensitivities and speciﬁ-
cities for 17 urine-based bladder tumour markers in
addition to urine cytology for patients undergoing
surveillance owing to a prior history of urothelial
carcinoma. As expected, the sensitivity of all urine
markers was higher than that of urine cytology for the
detection of recurrent bladder cancer. However, the
sensitivity was lower in the detection of recurrence
than in the detection of new tumours. The decreased
sensitivity for surveillance may be related to decreased
tumour stage, grade and size on surveillance com-
pared with screening, as has been described in other
reports [11,12]. The present ﬁndings conﬁrm these
previous ﬁndings, as shown in Tables I and II. In this
study, the performance characteristics of urine cytol-
ogy, Matritech’s NMP22 BladderChek test and Uro-
Vysion FISH test were chosen for assessment because
the last two are among the few tests currently
approved by the US FDA as urinary tumour markers
[13]. Furthermore, these two markers are different in
terms of cost, ease of use and their mechanisms of
action.
The nuclear matrix protein is responsible for cell
separation and chromatid regulation during mitosis
and is released during apoptotic cell death. The
available tests include a qualitative point-of-care
test that costs $ 10–30 per test and a quantitative
ELISA that costs $ 125–150 per test [7,14,15].
NMP22 testing appears to have decreased sensitivity
Table III. Performance characteristics of urine cytology (UC), nuclear matrix protein-22 (NMP22) and ﬂuorescence in situ hybridization
(FISH) tests in bladder cancer patients in remission.
Remission patients (tissue diagnosis)
UC (n = 56) NMP22 (n = 77) FISH (n = 25)
False positive 3 (5.4) 26 (33) 13 (52)
True negative 53 (95) 51 (67) 12 (48)
Data are shown as n (%).
n = number of tests performed for each tumour marker out of 77 patients in remission. Patients whose urine samples were not used for UC or
FISH had very few cells in the urine, in the category of patients with TCC of the bladder in remission.
Table IV. Performance characteristics of urine cytology (UC), nuclear matrix protein-22 (NMP22) and ﬂuorescence in situ hybridization
(FISH) tests in patients with bladder cancer.
Test
UC NMP22 FISH
Type of patient
ND TCC RCT TCC ND TCC RCT TCC ND TCC RCT TCC
Performance
(N = 43,
n = 10/36)
(N = 58,
n = 9/27)
(N = 43,
n = 31/38)
(N = 35,
n = 20/35)
(N = 43,
n = 33/41)
(N = 20,
n = 17/20)
Sensitivity (%) 28 33 82 57 80 85
Speciﬁcity (%) 95 95 66 67 48 48
PPV (%) 84.9 86.8 71.3 63 61 62
NPV (%) 84.1 58.6 78.8 60.9 71.2 76
Diagnostic accuracy (%) 62 64 74.5 62 64.5 61.5
ND = newly diagnosed; RCT = recurrent; TCC = transitional cell carcinoma; N = gross number of patients recruited in each category;
n = number of patients actually analysable in each category; PPV = positive predictive value; NPV = negative predictive value.
Reasons for difference between the tests: UC: small cellular material retrieved after centrifugation, equivocal NMP22 tests and no
chromosomes isolated by UroVysion FISH. Most of these were patients with very small tumours or small recurrences.
6 E. O. Kehinde et al.
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in detecting recurrent tumours (65% in primary
tumours and 45% in recurrent tumours) [12]. These
ﬁgures compare favourably with the present ﬁnding of
NMP22 sensitivity of 82% and 57% in patients with
newly diagnosed TCC bladder and those with recur-
rent bladder cancer, respectively. The lower sensitiv-
ity with recurrent cancer is presumably due to the
lower tumour burden in patients with recurrence and
hence a lower quantity of NMP22 in the urine. To
improve the sensitivity without sacriﬁcing the speci-
ﬁcity of NMP22 in patients with recurrent TCC
bladder, perhaps kits that can detect NMP22 values
as low as 2 U/ml can be produced, since the currently
available kits are designed to test positive if NMP22 in
urine is greater than 6 U/ml of NMP22. Patients who
were categorized as having an equivocal NMP22
result (Figure 1C) were probably those with small
low-grade or low-volume recurrences. In addition, as
highlighted above, false-positive rates can be as high
as 25% in the presence of non-tumour urological
disorders or within weeks of intravesical chemother-
apy. A false-positive rate of 33% was obtained. How-
ever, median sensitivity and speciﬁcity in surveillance
have been reported to be as high as 71 and 73%,
respectively [9]. A recent multicentre study assessed
the ability of NMP22 to detect recurrent cancer in
668 patients [16]. Recurrent cancer was identiﬁed in
103 patients (15.4%) and was mostly superﬁcial
(87%) and low grade (63%). The combination of
NMP22 and cystoscopy has been found to be more
sensitive than cystoscopy alone in detecting recur-
rences (99 vs 91%, p = 0.005) [9,16]. NMP22 has a
high NPV, which was as high as 91.2% in some series
[17]. In the present study, an NPV of 78.8% and
60.9% was found in patients with newly diagnosed
TCC and recurrent TCC, respectively. It has higher
sensitivity than cytology, with lower speciﬁcity (not
statistically signiﬁcant) (Table IV). Therefore, the
authors agree with others that it may potentially be
used in lieu of cytology in surveillance, offering cost
beneﬁts, improved sensitivity and potentially equiva-
lent speciﬁcity (in the absence of other genitourinary
conditions) [15]. Although a positive result could
result in unnecessary cystoscopy and/or biopsy, a
negative result may allow lengthening of the interval
between surveillance cystoscopies or prescreening
which patients require cystoscopy [7].
The FISH UroVysion is a laboratory-based assay
that uses colour-speciﬁc ﬂuorescent probes against
the centromeres on chromosomes 3, 7, 17 and
9p21 to detect common chromosomal aberrations
in exfoliated bladder cancer cells [8]. The test costs
approximately $475–700 per evaluation [14]. FISH
has been reported to have a median sensitivity of 79%
and a median speciﬁcity of 70% for surveillance of
recurrent tumours [9]. These data compare favour-
ably with the present data in patients undergoing
surveillance for TCC bladder, in which a sensitivity
of 85% and a speciﬁcity of 48%, respectively, were
found. However, FISH has been reported not to
perform well for high-grade disease and carcinoma
in situ, but sensitivity may not be much better than
cytology in the detection of low-grade and low-
stage recurrent tumours (36–60%) [18]. Therefore,
its utility in replacing cystoscopy has not yet been
clearly established and at best it may be better than
cytology in surveillance as it can be less equivocal;
however, it is far more expensive. Limitations of the
FISH test include its cost, the requirement for intact
urothelial cells and trained personnel with sophisti-
cated equipment, and an unstandardized deﬁnition of
a positive result [7]. Several patients were excluded
from analysis in this study because of a lack of suf-
ﬁcient cellular material, particularly in those with
recurrent diseases or in remission. This might have
affected some of the calculations. The authors agree
with Agarwal et al. [7] that, currently, FISH testing
should be reserved for select clinical situations rather
than used indiscriminately in surveillance.
In this comparative analysis UroVysion FISH had
high sensitivity in patients with newly diagnosed
(100%) or recurrent bladder TCC (100%). It had a
low speciﬁcity of 48% in all patients with TCC of
bladder. Presumably this is due to the fact that most of
the patients with TCC of the bladder have some
degree of instability of their urothelial chromosomal
pattern, giving rise to a high false-positive UroVysion
test. This is the subject of further investigations in this
centre. NMP22 had higher sensitivity and speciﬁcity
than cytology in all categories of patients with TCC.
NMP22 had lower sensitivity than FISH in patients
with newly diagnosed TCC or those with recurrence
(p not signiﬁcant).
From the data presented and those of others, it can
be argued that the current rigorous surveillance strat-
egies in patients with bladder cancer may be imposing
excessive diagnostic burden on patients with low-
grade disease for the sake of adequately monitoring
those with high-grade disease. This increases the
overall cost of management of patients with bladder
cancer. Although NMP22 has a high false-positive
rate, it is superior to cytology in sensitivity, and with
careful patient selection its speciﬁcity can be
improved. Given its high NPV, it may best be reserved
for determining patients in whom it may be possible to
extend the interval between subsequent cystoscopies.
The critical issue that remains to be answered is
whether these markers can reliably replace cystoscopy
and prolong the interval between direct visualization
without missing a recurrent tumour that could
Urinary tumour markers and bladder cancer 7
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potentially progress during the interval. In high-
risk patients, one option would be to use a cheap,
easy-to-perform marker with high sensitivity, such as
NMP22, in all patients undergoing surveillance as an
adjunct to cystoscopy. But instead of performing
cystoscopy for all patients with a positive NMP22,
a more speciﬁc marker such as FISH or cytology
could be used to clarify the results. A composite
picture may then emerge, which would avoid subject-
ing patients with low-risk disease to unnecessary
testing. More prospective studies are needed to prove
that low-risk patients can safely have cystoscopies at
longer intervals, with or without marker assays repla-
cing cystoscopy, and without affecting their disease-
speciﬁc survival. Such a strategy may lead to reduced
cost. However, it would have to be tailored to the
individual patient, such that the cost savings do not
come at the expense of the well-being of patients [6].
Other options worth exploring include the devel-
opment of NMP22 kits that can detect levels of
NMP22 as low as 2 U/ml, which may increase the
sensitivity NMP22 without sacriﬁcing its speciﬁcity,
especially in those with suspected recurrent disease
with small tumour burden. An alternative option may
be to explore serial measurements of urinary
NMP22 concentration and determine its role in
detecting recurrence, much like serum PSA in
patients with prostate cancer. Finally, combinations
of NMP22 and other tumour markers have been
shown to increase the sensitivity and the NPV of
NMP22 in the detection of recurrence of superﬁcial
urothelial tumours [19,20]. This stepwise approach of
tumour marker determination may be useful in the
future to reduce the frequency of surveillance cystos-
copies at a reasonable risk, particularly in patients
with low-grade superﬁcial tumours [19].
This study has some limitations. Only white light
cystoscopy was performed. Narrow-band imaging
cystoscopy is known to improve the detection of
recurrent superﬁcial bladder cancer compared with
white light cystoscopy [21]. In newly diagnosed
patients with bladder TCC, the performance charac-
teristic of urinary tumour markers could be improved
if analysis was performed in patients at high risk of
bladder cancer, such as older patients with gross
haematuria and smokers [22]. The exclusion of these
factors in the present study might have led to lower
speciﬁcity and sensitivity of the assessed tumour
markers. That is, the speciﬁcity of these tests is
different depending on the setting in which they are
used. For example, the NMP22 test has a much
higher speciﬁcity when used in the initial assessment
of patients with haematuria [22]. This study was
carried out in Kuwait, a Middle Eastern country
where the spectrum of bladder cancer presentation
is different from that in many Western countries. For
example, the age range of these patients is much lower
than in the West and the majority of patients were
smokers. These factors might have affected the results
although, as the data showed, not to any signiﬁcant
extent. Therefore, these tumour markers may have a
role in the management of patients with urothelial
tumours not only in Kuwait, but also in other parts of
the world.
In conclusion, at present, it does not appear that the
NMP22 BladderChek or the UroVysion FISH test
can replace cystoscopy in the initial diagnosis or
follow-up of patients with bladder cancer. However,
the NMP22 test could replace routine cytology in the
initial assessment of patients with suspected urothelial
cancer. Urine cytology has higher speciﬁcity than
NMP22 and FISH in bladder cancer patients without
tumour recurrence. FISH may not be an ideal urinary
tumour marker for surveillance in patients with blad-
der cancer because of its low speciﬁcity. Overall,
NMP22 appears to have the best performance char-
acteristics. Coupled with low cost and quick results,
NMP22 may be an ideal tumour marker to replace or
complement urine cytology in the management of all
categories of patients with urothelial cancer.
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